艾美捷科技代理Zenogen Pharma品牌。

Zenogen Pharma公司主要研发生产治疗性抗体、疫苗佐剂及细胞冻存培养基

（1）治疗性抗体：

通过建立可有效生产特异性抗体和功能性抗体的技术平台，并将其扩展到新药以及其他产品和服务的开发，FZENOGEN公司为创造更好的药物和诊断药物做出了贡献。

（2）疫苗佐剂：

Zenogen Pharma公司开发了一种颗粒聚合物，能够大大增加免疫系统的激活。这种聚合物具有成功提高体液和细胞免疫力的能力，我们发现它具有发挥和安全使用效果的潜力。

（3）细胞冻存培养基：

CELLBANKER是一系列细胞冻存培养基，对于大多数细胞系，该培养基在解冻后可实现80%以上的细胞活力。

STEM-CELLBANKER® GMP grade 细胞冻存液

STEM-CELLBANKER® DMSO Free GMP grade 细胞冻存液

STEM-CELLBANKER® EX GMP grade 细胞冻存液

HSC-BANKER® GMP grade 细胞冻存液

CELLBANKER® 1 细胞冻存液

CELLBANKER® 2 细胞冻存液

CELLOTION® 细胞冻存液

Innovative Research of America(IRA) 是一家致力研发于药物定量定时缓释系统的专业化公司，又称Matrix-Driven Delivery (MDD) 给药系统。该给药系统由一个可生物吸收的基质组成，含有定量可控的活性给药成分，可以以设定的剂量在一定时间范围内进行给药。

Since it is not easy to administer drugs and hormones orally to research animals, several delivery methods have been devised as alternatives.  However, most scientists continue to labor with unreliable injectables to conduct their research.

Matrix-Driven Delivery (MDD) Pellet（MDD片剂）的优势

Saves time

Ready-to-implant

Insures controlled product release over time

Avoids "peak and valley" effects

Guarantees consistent product preparation

Extends product life against spontaneous breakdown

Extends product life against host-related breakdown

Minimizes experimental variables

Insures safety of the experimenter

Reduces neurophysiological trauma to animal/no excessive handling

Generates more meaningful and reproducible results

Superior to conventional delivery methods

Enhances experimental efficiency

Frees valuable time for creative research

Saves money

Innovative Research of America的主要产品包括：

ANTIBIOTICS

ANTI-INFLAMMATORY AGENTS

ANTI-NEOPLASTICS

CATECHOLAMINES & RELATED PRODUCTS

CORTICOIDS & DIURETICS

ESTROGENS & ANTI-ESTROGENS

FATTY ACIDS

MISCELLANEOUS PRODUCTS

NUCLEOTIDE RELATED PRODUCTS

PLACEBO

PROGESTINS

PROSTAGLANDINS

THYROIDS

VITAMINS

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

Dendritics公司主要关注人类树突状细胞，希望找到能够促使CD34+造血前体细胞转化为树突状细胞（在GM-CSF和TNF-alpha存在的情况下）的细胞因子。在1992-2005年间，大量的研究使得研究者对人类树突状细胞的产生、细胞通路、C-type凝集素受体的功能及Toll-like受体的活性有了更深的理解。

DENDRITICS was started in 2005 by former members of SCHERING PLOUGH Laboratory for Immunological Research (LIR) in Dardilly, France. From their long experience at LIR, the team members of DENDRITICS have gathered complementary scientific and technological knowledge in different areas of immunology. The initial focus of LIR was in the biology of B lymphocytes, elaboration of human monoclonal antibodies, and in cytokine discovery (IL-3, IL-4, IL-7, IL-10, IL-17, GM-CSF) together with our colleagues of DNAX Research Institute in Palo Alto, California.

Our interest in cytokines led to the finding that human dendritic cells (DCs) could be generated in vitro from CD34+ hematopoietic progenitors cultured in the presence of GM-CSF and TNF-alpha.

The period from 1992 to 2005 saw the specialization of LIR in DC biology and was fuelled by a large-scale effort to discover and study the function of genes specifically expressed by these cells. This program led to a number of findings that contributed in particular to understanding the heterogeneity of DCs, the pathways regulating DC migration, the function of C-type lectin receptors in DCs and the activity of Toll-like receptors in DCs. Many novel genes were discovered through screening of cDNA libraries or through monoclonal antibodies raised against DCs.

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com